Precise Bio
Develops a 4D biofabrication platform for transplantable tissues and organs, combining cell expansion, biomaterials, and printing technology, with initial focus on corneal grafts for ophthalmology.
- CEO / Founder
- Aryeh Batt
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $27.5M
- Latest Round
- Series C
- Key Investors
- ZEISS; Aurum Ventures
Technology & Products
Key Products
4D biofabrication platform; Bio-printed corneal grafts (DSEK/DMEK/PK); Cardiac tissue patch for post-myocardial infarction; Ophthalmic pipeline including retinal patches and vision-correction lenticules
Technological Advantage
Verified advantage: First-in-animal corneal graft transplants demonstrated; claimed advantage: Platform designed for scalable manufacturing under GMP conditions. Defensible through proprietary processes and partnerships.
Differentiation
Value Proposition
Provides scalable, reproducible bio-fabricated tissues to address donor shortages, enabling on-demand production of clinical-grade human tissues like corneas with potential to reduce transplant wait times and improve outcomes.
How They Differentiate
Focus on 4D biofabrication for transplantable tissues with initial ophthalmology applications, offering higher reproducibility and scalability compared to standard 3D bioprinting; has achieved first animal corneal transplants and strategic partnership with Carl Zeiss Meditec.
Market & Competition
Target Customers
Hospitals, eye banks, clinicians in ophthalmology and regenerative medicine
Industry Verticals
Healthcare; Biotechnology; Regenerative Medicine
Competitors
Cellink; Aspect Biosystems; Organovo
Growth & Milestones
Growth Metrics
Raised $15.5M in funding; team size approximately 11-50 employees; progressing toward first-in-human trials for bioprinted corneas.
Major Milestones
First animal corneal graft transplant; Launch of ophthalmology business unit; Strategic partnership with Carl Zeiss Meditec; Advancement toward human trials for bioprinted corneas
Notable Customers
Carl Zeiss Meditec